This study was aimed to investigate whether the tumor necrosis induced by radiofrequency ablation (RFA) can improve the ratio of tumor-to-normal tissue (T/NT) after intratumoral injection of 131I-chTNT.
Materials and Method:
Eighteen New Zealand rabbits bearing VX2 tumor on the thigh were randomly divided into two treatment groups (control group: intratumoral injection of 131I-chTNT alone; RFA group: RFA + intratumoral injection of 131I-chTNT 3 days after RFA) and each group was further divided into three subgroups I, II, and III (1–2 cm, 2–3 cm, and 3–4 cm in maximum diameter, respectively), by the tumor size. SPECT was performed to evaluate the T/NT on days 1, 8, and 15 after 131I-chTNT injection.
Results:
After treatment, all rabbits underwent the SPECT whole-body scan and the T/NT was analyzed. The results showed that T/NT in the RFA group (55.45±41.83) was significantly higher compared with the control group (7.23±5.61) (F=18.89, p=0.001). Meanwhile, a linear ascending trend was found for T/NT in the RFA group along with the follow-up time (r=0.47, p=0.01). The tumor size or the dose of 131I-TNT injection had no significant effect on the variation of T/NT in both groups (p>0.05).
Conclusion:
RFA before intratumoral injection of 131I-chTNT can dramatically improve T/NT, demonstrating the potential application of this combination therapy.
Get full access to this article
View all access options for this article.
References
1.
TomblynM. Radioimmunotherapy for B-cell non-hodgkin lymphomas. Cancer Control, 2012; 19:196.
SrinivasanA, MukherjiSK. Tositumomab and iodine I131 tositumomab (Bexaar)AJNR Am J Neuroradiol, 2011; 32:637.
4.
HuangCY, PourgholamiMH, AllenBJ. Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. Cancer Treat Rev, 2012; 38:854.
5.
ChatalJF, DavodeauF, CherelMet al.Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. J Cancer Res Ther, 2009; 5,Suppl 1:S36.
6.
de JongGM, HendriksT, EekAet al.Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastases. Ann Surg, 2011; 253:336.
7.
de JongG, HendriksT, FranssenGet al.Adjuvant radioimmunotherapy after radiofrequency ablation of colorectal liver metastases in an experimental model. Eur J Surg Oncol, 2011; 37:258.
8.
KoppeMJ, PostemaEJ, AartsFet al.Antibody-guided radiation therapy of cancer. Cancer Metast Rev, 2005; 24:539.
SchoffelenR, van der GraafWT, FranssenGet al.Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med, 2010; 51:1780.
11.
SalaunPY, Bodet-MilinC, FrampasEet al.Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer, 2010; 116:1053.
12.
BarbetJ, ChatalJF. The best radionuclide for radioimmunotherapy of small tumors: Beta- or alpha-emitter?Eur J Nucl Med Mol Imaging, 2011; 38:271.
13.
SharkeyRM, RossiEA, McBrideWJet al.Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med, 2010; 40:190.
14.
SharkeyRM, KaracayH, GovindanSVet al.Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther, 2011; 10:1072.
15.
StreetHH, GorisML, FisherGAet al.Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm, 2006; 21:243.
16.
ChenFM, TaylorCR, EpsteinAL. Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res, 1989; 49:4578.
17.
ChenS, YuL, JiangCet al.Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol, 2005; 23:1538.
18.
EpsteinAL, ChenD, AnsariAet al.Radioimmunodetection of necrotic lesions in human tumors using I-131 labeled TNT-1 F (ab') 2 monoclonal antibody. Antibody Immunoconj Radiopharm, 1991; 4:151.
19.
ChenFM, LiuCZ, EpsteinAL. Effects of 131I-labeled TNT-1 radioimmunotherapy on HT-29 human colon adenocarcinoma spheroids. Cancer Immunol Immunother, 1991; 33:158.
20.
BruixJ, ShermanM. Management of hepatocellular carcinoma: An update. Hepatology, 2011; 53:1020.
21.
MirzaA, FornageB, SneigeNet al.Radiofrequency ablation of solid tumors. Cancer J, 2001; 7:95.
DewarajaYK, WildermanSJ, KoralKFet al.Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: A pilot patient study. Cancer Biother Radiopharm, 2009; 24:417.
29.
FrampasE, MaurelC, ThedrezPet al.The intraportal injection model for liver metastasis: Advantages of associated bioluminescence to assess tumor growth and influences on tumor uptake of radiolabeled anti-carcinoembryonic antigen antibody. Nucl Med Commun, 2011; 32:147.
30.
ZhangZ, BianH, FengQet al.Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther, 2006; 5:318.
31.
ChenZN, MiL, XuJet al.Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical phase I/II trials. Int J Radiat Oncol Biol Phys, 2006; 65:435.
32.
WuL, YangYF, GeNJet al.Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: Interim safety and survival data from 110 patients. Cancer Biother Radiopharm, 2010; 25:657.
33.
AndersonPM, WisemanGA, LewisBDet al.A phase I safety and imaging study using radiofrequency ablation (RFA) followed by 131I-chTNT-1/B radioimmunotherapy adjuvant treatment of hepatic metastases. Cancer Ther, 2003; 1:297.
